As the digital and social media revolution continues to evolve, healthcare marketers must consider how to unlock the full potential of social with innovative engagement opportunities.
What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.
Pandemic-reinforced principles of successful drug launch.
Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.
How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Are we letting momentum outpace readiness?
How one COVID-sparked model could help usher in needed reset.
The market for prescription medicines in the United States was subject to major shifts in use across therapeutic areas in 2022, reflecting changes in patient health needs, the development, and availability of novel medicines, and complex market dynamics.
Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
The industry holds the key to true change to the drug access landscape.
The pandemic has raised the stakes for companies pursuing new data-harnessing capabilities in contract management and KPI benchmarking and tracking.
Exploring practical points to further understand and strengthen quality culture.
Optimally designed SSO program can allow companies to deliver therapies to patients faster and at a more affordable cost.
Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.
Companies offering post-grad rotational programs develop broad skillsets in new hires.
With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.
The right market research insights provide a richer, more-nuanced picture of your customers as people, not just as numbers on a spreadsheet.
Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, missed insights, and costly rework.
Treating medical affairs solely as a support function is penny-wise and pound foolish. With the advent of machine learning, the medical affairs team can innovate and perform their many functions better and more efficiently.
Embracing business imperatives such as operational efficiency and a focus on a patient-centric approach can help pharma leaders provide a stable foundation amid lingering uncertainty.
Biopharma companies can foster patient-centered innovation by focusing on unmet needs along each stage of the patient journey while collaborating with key stakeholders directly or indirectly responsible for disease management.
Key Challenges for Manufacturers and How MilliporeSigma is Leading Industry-Wide Change